New hope for indian patients with Tough-to-Treat bladder cancer
NCT ID NCT06862219
Summary
This study is checking the safety of an existing cancer drug, enfortumab vedotin, specifically for Indian adults with advanced bladder cancer that has spread and has stopped responding to standard treatments. About 100 participants will receive the drug through an IV infusion every 4 weeks. The main goal is to monitor for side effects and see how well the drug is tolerated in this population.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site IN91001
RECRUITINGSurat, India
-
Site IN91004
RECRUITINGMumbai, Maharashtra, India
-
Site IN91005
RECRUITINGVaranasi, Uttar Pradesh, India
-
Site IN91008
RECRUITINGMumbai, India
-
Site IN91009
RECRUITINGNagpur, India
-
Site IN91010
RECRUITINGBhubaneswar, India
-
Site IN91012
RECRUITINGAhmedabad, India
-
Site IN91015
RECRUITINGKochi, Kerala, India
-
Site IN91016
RECRUITINGNew Delhi, National Capital Territory of Delhi, India
-
Site IN91017
RECRUITINGDumas, Surat, India
Conditions
Explore the condition pages connected to this study.